Page 38 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 2
51. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-671.
52. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040-2048.
53. Ahmed G, O’Keeffe J, Mullane DO, et al. Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase (DPD) deficiency in patients with colorectal cancer. J Clin Oncol. 2013;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2013.
54. Loganayagam A, Marinaki A, Arenas-Hernandez M, Fairbanks L, Sanderson J, Ross PJ. Prediction of severe 5-fluorouracil toxicity in gastro-intestinal cancer chemotherapy: role of DPD deficiency. J Clin Oncol. 2010;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2010.
55. Mercier C, Brunet C, Yang C, et al. Pharmacoeconomic study in head and neck cancer patients: Impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs. J Clin Oncol. 2009;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2009.
56. Etienne-Grimaldi MC, Ferrero J-M, Thomas F, et al. A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap). J Clin Oncol. 2013;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago: 20 May 2013.
57. Del Re M, Loupakis F, Michelucci A, et al. Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. J Clin Oncol. 2011;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2011.
58. Papadatos-pastos D, De Souza K, Karapanagiotou EM, Sandri I, Marinaki A, Mansi J. DPYD genotyping as a predictive biomarker of toxicity in breast cancer. Ann Oncol. 2014;Conference: 39th Congress of the European Society for Medical Oncology (ESMO).
59. Cubero DI, Cruz FM, Santi P, Silva ID, Del GA. Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol. 2012;4(4):167-172.
60. Van Schaik RHN. Clinical Application of Pharmacogenetics: Where are we now? eJIFCC. 2013;4(3- 4):1-8.
61. Siffert W. Pharmacogenetics in daily routine clinical practice. Drug Metabol Drug Interact. 2012;Conference: 6th Santorini Conference Biologie Prospective 2012 Santorini Island Greece. (var.pagings):A11-A12.
62. Onco Drug Personalized Medicine (ODPM). 2011; http://www.odpm.fr/. Accessed 3 February 2015.
63. Boisdron-Celle M, Capitain O, Metges J-P, et al. Severe Fluoropyrimidines toxicities: a simple and effective way to avoid them. Screen effectively for DPD deficiencies. Ann Oncol. 2012;Conference: 37th Congress of the European Society for Medical Oncology (ESMO).
64. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234.
65. FDA. U.S. Food and Drug Administration. Label information Xeloda (Capecitabine). 2015; www.
36